Xcelerate, Inc. Announces Appointment of New Board Member
Xcelerate, Inc. (OTC PINK:XCRT) has announced the acquisition of a portfolio of patents and technology licenses from HS Pharmaceuticals LLC, focusing on oncology and healthcare products. Mr. Jon Wilken, former President and CEO of BILO Inc., is joining Xcelerate's Board of Directors. Wilken brings 30 years of experience in retail and will assist in integrating the acquired patents into Xcelerate's business strategy. The company has also acquired a 51% stake in AfiyaSasa Africa, LLC, a medical technology firm leveraging AI and AR.
- Acquisition of a valuable portfolio of patents and technology licenses from HS Pharmaceuticals.
- Jon Wilken's extensive experience in retail and management could provide fresh perspectives to the board.
- Ongoing commitments to research in key medical fields such as oncology and wound healing.
- Concerns may arise over the continuity and experience gaps due to the new board member's background primarily in retail.
MAULDIN, SC / ACCESSWIRE / May 11, 2022 / Xcelerate, Inc. (OTC PINK:XCRT) recently announced that it had signed a purchase agreement to acquire a portfolio of patents, patents pending and technology licenses from HS Pharmaceuticals LLC, a company engaged in oncology research and the development of human and animal health care and medical products, as well as cosmetics and beauty products.
Today, the Company is pleased to announce that Mr. Jon Wilken, President and CEO of HS Pharmaceuticals is joining the Board of Directors of Xcelerate, Inc. Jon Wilken is a 30-year veteran of the retail food industry. He is the former President and CEO of BILO Inc., a supermarket chain which at the time of his employment was wholly owned by Ahold NV of The Netherlands. While Jon was at BILO, the company employed approximately 26,000 associates and operated over 400 retail supermarkets and convenience stores in four Southeastern States with annual sales of approximately
"The Board and I welcome Jon and look forward to collaborating with him on the various projects and, more especially, assisting in assimilating the recently acquired patent portfolio into our business plan. Jon has spent years coordinating the development of these patents and coordinating the efforts of various research scientists and universities." said Xcelerate CEO Michael O'Shea. "HS Pharmaceuticals has been shepherding these patents for the last 10+ years in conjunction with world renowned scientists and universities and we are excited to take this amazing intellectual property to the next level."
"I am looking forward to joining Mike and his team of health care and research professionals at XCRT. HS Pharma and its team of scientific and medical research professionals are committed to pursuing our promising researching in the fields of wound healing, oncology, bone regeneration, and autoimmune disorders, we are excited about the possibilities" commented Jon Wilken, President and CEO of HS Pharmaceuticals.
Vince Sordello, COO, HSP, will continue to monitor and maintain our patent (IP) portfolio and guide our research as we continue our quest for medical breakthrough science in wound healing, oncology, bone regeneration and autoimmune therapies.
About Xcelerate, Inc.
Xcelerate is a start-up, development stage company that has assembled an Advisory Board of internationally renowned translational clinicians and engineers to assist the Company in identifying and acquiring cutting-edge engineering technological advancements and intellectual property, most of which does not have immediately obvious applications to medical technology and clinical care. The Company goal is to acquire innovation at the engineering/patent level and develop med tech and clinical care applications.
Xcelerate has also recently acquired a
For more information, visit the company's website at http://Xcelerate.Global/
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
Xcelerate Contact
SOURCE: Xcelerate, Inc.
View source version on accesswire.com:
https://www.accesswire.com/700927/Xcelerate-Inc-Announces-Appointment-of-New-Board-Member
FAQ
What is the significance of Xcelerate's acquisition of HS Pharmaceuticals patents?
Who is Jon Wilken and what will he contribute to Xcelerate?
What does the 51% stake in AfiyaSasa Africa, LLC mean for Xcelerate?
What are the potential implications of the new board appointment on Xcelerate's strategy?
